26-Dec-2025
No headlines found.
Business Wire (Mon, 1-Dec 9:00 AM ET)
MaxCyte Announces Planned CFO Transition in 2026
Globe Newswire (Wed, 12-Nov 4:08 PM ET)
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
Globe Newswire (Wed, 12-Nov 4:05 PM ET)
Globe Newswire (Wed, 5-Nov 8:05 AM ET)
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
Globe Newswire (Wed, 8-Oct 8:05 AM ET)
Globe Newswire (Mon, 6-Oct 8:05 AM ET)
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Maxcyte trades on the NASDAQ stock market under the symbol MXCT.
As of December 26, 2025, MXCT stock price climbed to $1.61 with 372,840 million shares trading.
MXCT has a beta of 1.03, meaning it tends to be more sensitive to market movements. MXCT has a correlation of 0.07 to the broad based SPY ETF.
MXCT has a market cap of $171.64 million. This is considered a Micro Cap stock.
Last quarter Maxcyte reported $7 million in Revenue and -$.12 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.02.
In the last 3 years, MXCT traded as high as $6.02 and as low as $1.26.
The top ETF exchange traded funds that MXCT belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
MXCT has underperformed the market in the last year with a return of -60.4%, while SPY returned +16.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MXCT shares. However, MXCT has outperformed the market in the last 3 month and 2 week periods, returning +5.2% and +5.9%, while SPY returned +4.6% and +1.5%, respectively. This indicates MXCT has been having a stronger performance recently.
MXCT support price is $1.53 and resistance is $1.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MXCT shares will trade within this expected range on the day.